Running a clinical trial in India as a U.S. sponsor comes down to five decisions, made in the right order: get the regulatory pathway right, file with the CDSCO, choose sites on capability rather than convenience, build the operational plan around enrollment, and govern the whole thing to the standard your FDA filing will demand. Get that sequence right and India is one of the fastest credible places in the world to run a trial. Get it wrong and you inherit the offshore friction that has burned sponsors before.
Most guides to running a trial in India read like a brochure. This one is the actual sequence, written for a sponsor who has never filed in the country and wants to know what really happens.
Step 1 — Decide whether India belongs in your plan at all
Before any paperwork, answer one question: why India? If the honest answer is only “it’s cheaper,” you are likely to make the wrong decisions downstream. The strongest reasons are patient access — India’s high-volume cancer centers and broad patient populations — and, for certain subtypes, the fact that the disease is simply more common there. Cost savings are real, but they follow from getting the patient and operational decisions right; they are not the reason to go.
This is also the point to map your global filing strategy. A trial run in India should be designed from the start to support your FDA — and, where relevant, EMA or PMDA — submission. Deciding that after the protocol is locked is how sponsors end up running the same study twice.
Step 2 — Set the regulatory pathway with the DCGI in view
India’s drug regulator is the Central Drugs Standard Control Organisation (CDSCO), and the final authority on a clinical trial is the Drugs Controller General of India (DCGI). The governing rules are the New Drugs and Clinical Trials Rules, 2019 (NDCT 2019).
The key thing for a foreign sponsor to understand is that India does not run on “proceed unless told otherwise.” Unlike the U.S. IND, where a trial can begin 30 days after submission absent a hold, India generally requires affirmative permission before you start. You design around that default, not against it.
It is also worth checking early whether your program qualifies for a local-trial waiver under Rule 101 — if your drug is already approved in a recognised market and fits a defined category, you may not need a fresh India trial at all. That is a strategy decision to make before you build a protocol you may not need.
Step 3 — File through Sugam and prepare for the Subject Expert Committee
CDSCO applications are submitted online through the Sugam portal. The application is then reviewed by a Subject Expert Committee (SEC) — a panel of specialists in the relevant therapeutic area who evaluate the protocol, the pre-clinical and clinical data, and the rationale.
Treat the SEC the way you would treat an FDA meeting. The committee reads your application its own way, and an unanticipated query can add a review cycle and cost a quarter. Sponsors who clear cleanly are the ones who anticipated the questions before submitting, not after.
Step 4 — Select sites on capability, not convenience
This is where trials are won or lost. The fastest way to stall a study is to spread it thinly across many low-volume sites that each contribute a patient or two. The better approach is to concentrate enrollment in premier, high-volume centers with genuine investigator depth in your indication, strong diagnostic infrastructure, and inspection readiness.
For oncology especially, site strategy is enrollment strategy. A smaller number of deep sites beats a long list of shallow ones almost every time.
Step 5 — Build the operation around enrollment, and govern it to one standard
With the pathway and sites set, the operational plan — site activation, patient recruitment, biomarker and tissue logistics where relevant, monitoring, and data management — should be built around the single hardest variable: finding and enrolling the right patients fast enough. Tissue logistics and central-lab confirmation, in particular, are where eligible patients quietly drop out if the chain is not designed deliberately.
Throughout, the documentation standard should be the one a U.S., EU, or Japanese sponsor expects in an inspection. The advantage of an in-house, DCGI-registered operation over a chain of subcontractors is precisely this: one accountable owner from protocol to database lock, one written standard held across both geographies.
The shortcut that isn’t
The temptation is to treat India as a place to send a finished protocol cheaply. The sponsors who get value do the opposite: they bring India into the strategy early, design the program around it, and run it through one accountable team. The sequence above is that approach, compressed.
Frequently asked questions
Q: Is data from an India clinical trial acceptable to the FDA? A: Yes, when the trial is designed and documented to FDA standards from the outset. The development and documentation plan has to be built for your target agencies from the start, and every operational step documented to inspection standard.
Q: How long does CDSCO approval take? A: Timelines depend on the application and the Subject Expert Committee review. A clean, well-prepared submission moves faster than one that triggers queries — which is why preparation for the SEC matters as much as the dossier itself.
Q: Do I need a local entity or agent to run a trial in India? A: Foreign sponsors work through a registered local capability. The cleanest model is an in-house, DCGI-registered CRO that owns delivery, rather than coordinating across an adviser, a CRO, and a separate local agent.
Considering India for an oncology or biopharma program? Talk to the regulatory and development leads who would actually run it. → eteraflexconnects.com
